PELACARSEN
Total Payments
$177,793
Transactions
36
Doctors
13
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $177,793 | 36 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $105,386 | 11 | 59.3% |
| Consulting Fee | $72,407 | 25 | 40.7% |
Payments by Type
Research
$105,386
11 transactions
General
$72,407
25 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEVELS AMONG PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE | Novartis Pharmaceuticals Corporation | $80,311 | 0 |
| A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE | Novartis Pharmaceuticals Corporation | $25,076 | 0 |
Top Doctors Receiving Payments for PELACARSEN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houma, LA | $105,386 | 11 |
| , M.D | Cardiovascular Disease | New York, NY | $9,062 | 2 |
| , MD | Cardiovascular Disease | Boca Raton, FL | $8,910 | 2 |
| , DO | Cardiovascular Disease | Portland, OR | $7,200 | 2 |
| , MD | Cardiovascular Disease | New York, NY | $7,200 | 2 |
| , M.D | Cardiovascular Disease | Torrance, CA | $6,086 | 2 |
| , MD | Cardiovascular Disease | Bloomfield Township, MI | $5,963 | 2 |
| , MD, MPH | Cardiovascular Disease | New Haven, CT | $5,280 | 2 |
| , M.D | Internal Medicine | Temple, TX | $4,463 | 2 |
| , M.D | Internal Medicine | Atlanta, GA | $4,463 | 2 |
| , MD | Internal Medicine | Newton, MA | $4,001 | 2 |
| , MD | Internal Medicine | Philadelphia, PA | $3,935 | 2 |
| , MD, PHD | Cardiovascular Disease | Portland, OR | $3,935 | 2 |
| , M.D | Internal Medicine | Kansas City, KS | $1,908 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $177,793
Product Information
- Type Drug
- Total Payments $177,793
- Total Doctors 13
- Transactions 36
About PELACARSEN
PELACARSEN is a drug associated with $177,793 in payments to 13 healthcare providers, recorded across 36 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2020 to 2020. In 2020, $177,793 was paid across 36 transactions to 13 doctors.
The most common payment nature for PELACARSEN is "Unspecified" ($105,386, 59.3% of total).
PELACARSEN is associated with 2 research studies, including "MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEVELS AMONG PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE" ($80,311).